Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Operating Income (2016 - 2025)

Altimmune (ALT) has disclosed Operating Income for 16 consecutive years, with $46.9 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 19.53% to $46.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$18.6 million through Dec 2025, up 6.59% year-over-year, with the annual reading at -$18.6 million for FY2025, 6.59% up from the prior year.
  • Operating Income for Q4 2025 was $46.9 million at Altimmune, up from -$20.9 million in the prior quarter.
  • The five-year high for Operating Income was $58.3 million in Q4 2024, with the low at -$33.6 million in Q4 2023.
  • Average Operating Income over 5 years is -$16.0 million, with a median of -$22.7 million recorded in 2023.
  • The sharpest move saw Operating Income plummeted 123.12% in 2021, then surged 273.52% in 2024.
  • Over 5 years, Operating Income stood at -$24.0 million in 2021, then grew by 3.71% to -$23.1 million in 2022, then plummeted by 45.59% to -$33.6 million in 2023, then soared by 273.52% to $58.3 million in 2024, then fell by 19.53% to $46.9 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at $46.9 million, -$20.9 million, and -$22.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.